What are the standard first-line treatments for metastatic castration-resistant prostate cancer

Standard First-Line Treatments for Metastatic Castration-Resistant Prostate Cancer

Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that has spread beyond the prostate and no longer responds to hormone-lowering therapy. Here's what the current treatment landscape looks like:

Current Standard Approaches

According to the medical literature and expert consensus, first-line treatment for mCRPC typically involves:

1. Taxane Chemotherapy

Docetaxel or Cabazitaxel are chemotherapy drugs commonly used as initial treatment. These work by disrupting cancer cell division. Docetaxel is often used first, with cabazitaxel reserved for patients who progress after docetaxel or cannot tolerate it.

2. Androgen Receptor-Targeted Therapies

These medications work by blocking the androgen receptor (the protein that allows testosterone to fuel cancer growth):

• Abiraterone acetate (blocks testosterone production)
• Enzalutamide (blocks androgen receptor signaling)
• Darolutamide (newer androgen receptor inhibitor)

These are often combined with hormone-lowering therapy (ADT - androgen deprivation therapy).

3. Emerging Immunotherapy Approaches

According to Dr. [removed] Subudhi's research on immunotherapies for mCRPC, the field is moving toward immune-based treatments. Current approaches being studied include:

• Immune checkpoint inhibitors (like anti-CTLA-4 and anti-PD-L1 agents)
• Therapeutic vaccines (like Sipuleucel-T/Provenge)
• T-cell bispecific therapies - described as "the backbone of immunotherapy treatments in prostate cancer" going forward
• CAR T-cell therapies targeting PSMA (prostate-specific membrane antigen)

Important Considerations

Treatment Selection Depends On:

• Your specific genetic mutations (BRCA, DNA repair genes, PARP sensitivity)
• Prior treatments you've received
• Your overall health and ability to tolerate side effects
• Metastasis location (bone vs. soft tissue)
• Your PSA level and rate of rise

Genetic Testing Matters: As noted in the molecular tumor board discussion, genetic testing (like Foundation One testing) can reveal mutations that make you eligible for targeted therapies like PARP inhibitors, which may be particularly effective if you have DNA repair gene mutations.

Questions to Ask Your Oncologist

1. What is my specific genetic profile, and do I have any mutations that would make me eligible for targeted therapies?
2. Which first-line treatment do you recommend for my situation, and why?
3. Are there clinical trials available that match my genetic profile or disease characteristics?
4. How will we monitor treatment response (PSA, scans, other markers)?
5. What are the expected side effects, and how will we manage them?
6. If my current treatment stops working, what are the next options?

A Note on Treatment Sequencing

The order and combination of treatments matters significantly. Your oncologist will consider what you've already received and what options remain. This is why working with a genitourinary medical oncologist (a specialist in urologic cancers) is particularly valuable—they have expertise in sequencing these complex treatment decisions.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.